PL3618811T3 - Proces wytwarzania porowatych cząsteczek krzemionki załadowanych co najmniej jednym związkiem bioaktywnym dostosowanych do dostarczania dopłucnego, donosowego, podjęzykowego i/lub dogardłowego - Google Patents

Proces wytwarzania porowatych cząsteczek krzemionki załadowanych co najmniej jednym związkiem bioaktywnym dostosowanych do dostarczania dopłucnego, donosowego, podjęzykowego i/lub dogardłowego

Info

Publication number
PL3618811T3
PL3618811T3 PL18723453T PL18723453T PL3618811T3 PL 3618811 T3 PL3618811 T3 PL 3618811T3 PL 18723453 T PL18723453 T PL 18723453T PL 18723453 T PL18723453 T PL 18723453T PL 3618811 T3 PL3618811 T3 PL 3618811T3
Authority
PL
Poland
Prior art keywords
sublingual
nasal
lung
silica particles
porous silica
Prior art date
Application number
PL18723453T
Other languages
English (en)
Inventor
Adam Feiler
Chunfang Zhou
Paulina PASZKIEWICZ
Xin XIA
Original Assignee
Nanologica Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanologica Ab filed Critical Nanologica Ab
Publication of PL3618811T3 publication Critical patent/PL3618811T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5015Organic compounds, e.g. fats, sugars
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01BNON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00Silicon; Compounds thereof
    • C01B33/113Silicon oxides; Hydrates thereof
    • C01B33/12Silica; Hydrates thereof, e.g. lepidoic silicic acid
    • C01B33/124Preparation of adsorbing porous silica not in gel form and not finely divided, i.e. silicon skeletons, by acidic treatment of siliceous materials
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00Physical properties of inorganic compounds
    • C01P2006/14Pore volume
    • CCHEMISTRY; METALLURGY
    • C01INORGANIC CHEMISTRY
    • C01PINDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00Physical properties of inorganic compounds
    • C01P2006/16Pore diameter

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18723453T 2017-05-04 2018-05-03 Proces wytwarzania porowatych cząsteczek krzemionki załadowanych co najmniej jednym związkiem bioaktywnym dostosowanych do dostarczania dopłucnego, donosowego, podjęzykowego i/lub dogardłowego PL3618811T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1750544 2017-05-04
PCT/EP2018/061436 WO2018202818A1 (en) 2017-05-04 2018-05-03 A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery
EP18723453.9A EP3618811B1 (en) 2017-05-04 2018-05-03 A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery

Publications (1)

Publication Number Publication Date
PL3618811T3 true PL3618811T3 (pl) 2021-04-06

Family

ID=62143135

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18723453T PL3618811T3 (pl) 2017-05-04 2018-05-03 Proces wytwarzania porowatych cząsteczek krzemionki załadowanych co najmniej jednym związkiem bioaktywnym dostosowanych do dostarczania dopłucnego, donosowego, podjęzykowego i/lub dogardłowego

Country Status (11)

Country Link
US (1) US11285107B2 (pl)
EP (1) EP3618811B1 (pl)
JP (1) JP7048642B2 (pl)
KR (1) KR102579524B1 (pl)
CN (1) CN110603034A (pl)
AU (1) AU2018262708B2 (pl)
CA (1) CA3059099C (pl)
DK (1) DK3618811T3 (pl)
ES (1) ES2837675T3 (pl)
PL (1) PL3618811T3 (pl)
WO (1) WO2018202818A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018202818A1 (en) 2017-05-04 2018-11-08 Nanologica Ab A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery
GB201818164D0 (en) 2018-11-07 2018-12-19 Vicore Pharma Ab New composition
JP7394493B2 (ja) * 2019-07-31 2023-12-13 レモネックス インコーポレイテッド 抗癌剤および多孔性シリカ粒子の製造方法
GB201916122D0 (en) 2019-11-06 2019-12-18 Nanologica Ab New compositions
GB201916130D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916117D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
GB201916121D0 (en) 2019-11-06 2019-12-18 Vicore Pharma Ab New compositions
WO2021211738A1 (en) * 2020-04-15 2021-10-21 Sanford Burnham Prebys Medical Discovery Institute Methods and compositions for antiviral treatment
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
GB2355711B (en) 1999-10-27 2003-12-24 Agilent Technologies Inc Porous silica microsphere scavengers
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6485707B2 (en) 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6596262B2 (en) 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0118689D0 (en) 2001-08-01 2001-09-19 Psimedica Ltd Pharmaceutical formulation
US20040242729A1 (en) 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
FI20060428L (fi) 2006-05-03 2007-11-04 Esko Kauppinen Pintamodifioidut aerosolihiukkaset, menetelmä ja laite niiden tuottamiseksi sekä jauheet ja dispersiot jotka sisältävät kyseisiä hiukkasia
CN101918312A (zh) 2007-06-04 2010-12-15 全技术联合公司 二氧化硅颗粒及其制备方法和使用方法
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
US20090118249A1 (en) 2007-09-07 2009-05-07 Ingo Friedrich Dheas inhalation compositions
AU2009214118B2 (en) 2008-02-11 2014-06-12 Nanologica Ab Method for manufacturing mesoporous materials, materials so produced and use of mesoporous materials
AU2009224418B2 (en) 2008-03-11 2014-12-11 Aska Pharmaceutical Co., Ltd. Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both
WO2012035074A1 (en) 2010-09-14 2012-03-22 Nanologica Ab Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients
GB201212866D0 (en) * 2012-07-20 2012-09-05 Formac Pharmaceuticals Nv Dry granulates of mesoporous silica powders
JP2017510624A (ja) 2014-02-10 2017-04-13 パタラ ファーマ リミテッド ライアビリティ カンパニー 肥満細胞安定剤による全身性障害の治療
WO2016013751A1 (ko) * 2014-07-22 2016-01-28 주식회사 레모넥스 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도
US20160090603A1 (en) 2014-09-30 2016-03-31 Sandia Corporation Delivery platforms for the domestication of algae and plants
WO2017023407A2 (en) * 2015-06-01 2017-02-09 Stc. Unm Nanobiocomposite compositions and methods
CN109069769A (zh) * 2016-02-29 2018-12-21 埃姆普里居公司 用于蒸发和吸入活性剂的装置
WO2018202818A1 (en) 2017-05-04 2018-11-08 Nanologica Ab A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery

Also Published As

Publication number Publication date
WO2018202818A1 (en) 2018-11-08
AU2018262708B2 (en) 2021-06-03
JP2020518620A (ja) 2020-06-25
KR20190142386A (ko) 2019-12-26
EP3618811A1 (en) 2020-03-11
EP3618811B1 (en) 2020-09-30
US20200069588A1 (en) 2020-03-05
CN110603034A (zh) 2019-12-20
US11285107B2 (en) 2022-03-29
JP7048642B2 (ja) 2022-04-05
AU2018262708A1 (en) 2019-11-28
ES2837675T3 (es) 2021-07-01
DK3618811T3 (da) 2020-12-21
CA3059099C (en) 2023-06-27
KR102579524B1 (ko) 2023-09-18
CA3059099A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
PL3618811T3 (pl) Proces wytwarzania porowatych cząsteczek krzemionki załadowanych co najmniej jednym związkiem bioaktywnym dostosowanych do dostarczania dopłucnego, donosowego, podjęzykowego i/lub dogardłowego
AU201712950S (en) Respiratory mask with air delivery aadapter
PL3892127T3 (pl) Papieros elektroniczny z masowym czujnikiem przepływu powietrza
HK1257973A1 (zh) 確定用於媒體傳輸的媒體傳遞事件位置
IL263339A (en) Nicotine inhaler system
PL3093567T3 (pl) Zasobnik filtra, walec i nawilżacz powietrza
EP3298911A4 (en) Electronic cigarette with integrated suction nozzle
PL3288401T3 (pl) Wyrób do wytwarzania aerozolu zawierający odłączalny element dostarczający odświeżacz z silną wentylacją
WO2012110258A3 (de) Rauchfreie zigarette, zigarre oder pfeife
EP2987544A4 (en) FILTER MATERIAL FOR AN AIR FILTER, MANUFACTURING METHOD AND AIR FILTER THEREFOR
IL292251A (en) Use of anti-static materials in air passages in the process of thermal condensation of an aerosol
PL3694349T3 (pl) Inhalator, w szczególności elektroniczny produkt papierosowy
PL3508078T3 (pl) Zestaw papierosowy do wdychania przez nos typu naciskowego z funkcją podgrzewania
DK3522962T3 (en) A nasal delivery system
PL3099641T3 (pl) Podłoże zaopatrzone w powłokę na bazie topnika do szkła, materiał stanowiący topnik do szkła oraz sposób powlekania podłoża szklanego lub szklano-ceramicznego
HK1219941A1 (zh) 化學强化碱鋁硅酸鹽玻璃用玻璃組合物及其製造方法
IL269275A (en) Container with particles for use with an inhaler
CA189046S (en) Mist inhaler
IL288764A (en) Steam supply systems
PL3727256T3 (pl) Wyrób chłonny o zmniejszonym osiadaniu oraz sposób wytwarzania tego wyrobu chłonnego
PL3481472T3 (pl) Materiał ekspoatacyjny do dostarczania nikotyny w postaci cząstek
PL3310731T3 (pl) Wyrób powlekany sekwencyjnie aktywowaną powłoką niskoemisyjną i/lub sposób jego wytwarzania
HK1199142A1 (en) Mercury vapour discharge lamp and method for the manufacture thereof
EP3418256A4 (en) METHOD FOR MANUFACTURING POROUS SILICA PARTICLE OF C UR-BARK TYPE
ZA201309161B (en) Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion